Adaptin Bio (APTN) EPS (Basic) (2023 - 2026)

Adaptin Bio has disclosed EPS (Basic) across 4 years of filings, most recently posting -$0.13 for Q1 2026.

• Quarterly EPS (Basic) fell 30.0% year-over-year to -$0.13 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.67 (up 29.47% YoY) and the FY2025 annual result came in at -$0.66, up 31.25% from the prior year.
• EPS (Basic) grew to -$0.13 in Q1 2026, from -$0.16 in the prior quarter.
• Across five years, EPS (Basic) topped out at -$0.0 in Q1 2023 and bottomed at -$0.34 in Q3 2024.
• The 4-year median for EPS (Basic) is -$0.13 (2026), against an average of -$0.13.
• Year-over-year, EPS (Basic) slumped 24900.0% in 2024 and surged 41.18% in 2025.
• Adaptin Bio's EPS (Basic) stood at -$0.01 in 2023, then tumbled by 3614.29% to -$0.26 in 2024, then jumped by 38.46% to -$0.16 in 2025, then advanced by 18.75% to -$0.13 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$0.13, -$0.16, and -$0.2 for Q1 2026, Q4 2025, and Q3 2025 respectively.